| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Double Entry Bookkeeping |
|
Useful Advices - Double Entry Bookkeeping
Double-entry Bookkeeping is one of the standard accounting practices for recordi According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ng financial transactions. Five hundred years ago it was codified for the first ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in time by Luca Pacioli. The conceptual framework is that a business can be descri lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. bed by a number of different accounts, each describing an aspect of the business here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe in monetary terms. Every transaction in double-entry Bookkeeping has a dual eff d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ect; for example, buying machinery means losing cash but gaining the monetary va ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc lue of the machinery. Double-entry Bookkeeping works on the principle that asse easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ts are the summation of liabilities and equity. For the accounts to remain in ba nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically lance, a change in one account must be matched with a change in another account. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ These changes are known as debits and credits. Debit and credit are interrelate ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ; when an account is debited another account in relation is credited. Assets and ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a accounts receivable are treated as debits, while liabilities and accounts payab dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod le are treated as credits. The use of debit or credit to increase or decrease a cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin n account depends on the normal balance of the account. To close the books of ac tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen counts, the accountant will adjust expenses and revenues by appropriately credit t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ing and debiting the income summary. Credit and debit items are summarized at th ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust e end of a recording period in a trial balance. A trial balance is a list of all y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products the debits and credits. The debits and credits must be matched in the trial bal . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ance. The trial balance is used as the basis for the preparation of the balance elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip sheet and a profit and loss account, and also used for error-checking mechanisms tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Young Men in Business Battling the Good Ole' Boy Network
|